WideScreen™ Assays for the Luminex® xMAP® platform

Follow the links below for more information on WideScreen Assays including: Certificates of Analysis Validation information Protocols Scientific poster reprints Articles Upcoming panels and assays

WideScreen™ EpiTag™ Assays Overview Technology ERK Data Available Assays WideScreen™ RTK Assays RTK Assays RTK Data Available Assays WideScreen™ Biomarker Assays Human Cancer Panel 1 (Tumor Markers) Human Cancer Panel 2 (Growth Factors)

The WideScreen Multiplex Assays use xMAP® Technology for the detection of biomarkers and signaling proteins. Using a familiar sandwich immunoassay format, dye-labeled xMAP microspheres are used to create assays for the detection of multiple analytes from the same reaction, resulting in savings in sample, costs, and time. Samples are combined with coded xMAP microspheres covalently conjugated to a capture antibody. After incubation, analytes captured by the beads are identified with detection antibodies and a fluorescent label. Signals are detected on a Luminex instrument, which uses dual lasers to identify the bead and the fluorescent signal from the label.

WideScreen Multiplex Assays for intracellular signaling proteins
Novagen offers a variety of technologies for the detection of total and phosphorylated proteins important in cell biology and therapeutic compound development.
 WideScreen RTK Assays - are for the detection of total levels and phosphotyrosine modification (activation) status of key receptor tyrosine kinases.
 WideScreen EpiTag™ ERK Pathway Assays - detect key signaling events in the ERK/MAPK pathway from both human and mouse samples and are the only multiplex xMAP assays available that enable the quantitation of both total and phosphorylated protein from a single sample in the same well.

WideScreen Multiplex Assays for extracellular proteins
Novagen is committed to developing state of the art assays for serum, plasma and tissue culture supernatant samples. WideScreen Biomarker Assays are the result of an ongoing collaboration between Novagen and Rules Based Medicine, the industry leading biomarker testing laboratory for large scale and clinical trial projects. WideScreen Biomarker Assay are multiplex kits, or panels, are created using assays from RBM’s HumanMAP® and RodentMAP® service portfolio focusing on specific therapeutic areas and disease states.